Alternating combination chemotherapy C-MOPP (cyclophosphamide, vincristine, procarbazine, prednisone) and ABVd (adriamycin, bleomycin, vinblastine, dacarbazine) in clinical stage II-IV Hodgkin's disease: a multicenter phase II study (JCOG 8905). The Lymphoma Study Group of the Japan Clinical Oncology Group. Japanese Journal of Clinical Oncology 30(3): 146-152, 2000
Treatment of Hodgkin's disease in children with alternating mechlorethamine, vincristine, procarbazine, and prednisone (MOPP) and adriamycin, bleomycin, vinblastine, and dacarbazine (ABVD) courses without radiotherapy. Medical and Pediatric Oncology 29(1): 23-27, 1997
Chemotherapy of hodgkin's lymphoma with alternating cycles of copp cyclophosphamide vincristine procarbazine prednisone and abvd doxorubicin bleomycin vinblastine and dacarbazine results of the hd1 and hd3 trials of the german hodgkin study group. Medical Oncology and Tumor Pharmacotherapy 6(2): 155-162, 1989
Doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) salvage of mechlorethamine, vincristine, prednisone, and procarbazine (MOPP)-resistant advanced Hodgkin's disease. Cancer Treatment Reports 68(7-8): 947-951, 1984
Gonadal toxicity after combination chemotherapy for hodgkins disease comparative results of mopp mechlorethamine vincristine procarbazine and prednisone vs. adriamycin bleomycin vinblastine and dacarbazine. European Journal of Cancer and Clinical Oncology 21(5): 601-606, 1985
Lomustine, etoposide, vindesine, and dexamethasone (CEVD) in Hodgkin's lymphoma refractory to cyclophosphamide, vincristine, procarbazine, and prednisone (COPP) and doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD): a multicenter trial of the German Hodgkin Study Group. Cancer Treatment Reports 71(12): 1203-1207, 1987
Hybrid chemotherapy consisting of cyclophosphamide, vincristine, procarbazine, prednisone, doxorubicin, bleomycin, and vinblastine (C-MOPP/ABV) as first-line treatment for patients with advanced Hodgkin disease. Cancer 88(9): 2142-2148, 2000
Treatment of Hodgkins disease in children with alternating mechlorethamine, vincristine, procarbazine, and prednisone and adriamycin, bleomycin, vinblastine, and dacarbazine courses without radiotherapy. Medical & Pediatric Oncology 29(1): 23-27, 1997
Chemotherapy vs radiotherapy for remission consolidation after three double cycles of cyclophosphamide vincristine procarbazine prednisone copp and doxorubicin bleomycin vinblastine dacarbazine abvd a randomized trial in patients with stages iiib iv hodgkins lymphoma. Journal of Cancer Research & Clinical Oncology 116(Suppl. Part 1): 613, 1990
Treatment of MOPP-resistant Hodgkin's disease with adriamycin, bleomycin, vinblastine and dacarbazine (ABVD). European Journal of Cancer and Clinical Oncology 18(9): 803-806, 1982
Combination chemotherapy of MOPP-resistant Hodgkin's disease with adriamycin, bleomycin, dacarbazine and vinblastine (ABDV). Cancer 39(4): 1382-1386, 1977
Treatment of mechlorethamine vincristine procarbazine prednisone resistant hodgkins disease with adriamycin bleomycin vinblastine and dacarbazine. European Journal of Cancer & Clinical Oncology 18(9): 803-806, 1982
Prolonged disease-free survival in MOPP-resistant Hodgkin's disease after treatment with adriamycin, bleomycin, vinblastine and dacarbazine (ABVD). Cancer ChemoTherapy and Pharmacology 2(2): 101-105, 1979
Efficacy of lomustine, teniposide, doxorubicin, bleomycin and prednisone (LTABP) or adriamycin, bleomycin, vinblastine and dacarbazine (ABVD) in the treatment of malignant lymphogranulomatosis resistant to MOPP. Polski Tygodnik Lekarski 45(21-22): 426-429, 1990
Combined modality therapy of advanced recurrent hodgkins disease a randomized trial testing bcg methanol extraction residue immuno therapy and chemo therapy of 1 2 chloroethyl 3 cyclohexyl 1 nitroso urea vinblastine procarbazine prednisone and bleomycin adriamycin vincristine streptozotocin and alternating sequences of 1 2 chloroethyl 3 cyclohexyl 1 nitroso urea vinblastine procarbazine prednisone and bleomycin adriamycin vincristine streptozotocin. Cancer Treatment Reports 66(4): 1065, 1982